Company / Shareholders' Equity
Stoke Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$352.5M
FY2025
5-year range
$159.6M / $352.5M
FY2021-FY2025
Trend
+120.9%
vs FY2024
Sector context
#117 of 213
Health Care
What the data says
At $352M, Stoke Therapeutics, Inc.'s shareholders' equity ranks #117 of 213 in the Health Care sector. Shareholders' Equity returned to growth in FY2025 after 2 years of decline, reaching $352M.
Based on SEC 10-K filings.
$352M in FY2025 with a 5-year CAGR of +4.3%.
Improved from $185M to $352M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +17.4%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Sector benchmark
#117 of 213 in Health CareTop 55% of 213This company $352.5M Sector average $2.5B
▼
-86.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 120.9% year-over-year.
- Ranks #117 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $352.5M | +120.9% |
| FY2024 | $159.6M | -13.7% |
| FY2023 | $184.8M | -15.1% |
| FY2022 | $217.8M | +0.0% |
| FY2021 | $217.8M | -23.9% |
| FY2020 | $286.1M | +27.5% |
| FY2019 | $224.4M | +113.6% |
| FY2018 | $105.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026